Merck Total Non-Operating Income/Expense 2010-2024 | MRK
Merck annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
- Merck total non-operating income/expense for the quarter ending June 30, 2024 was $-0.122B, a 62.23% decline year-over-year.
- Merck total non-operating income/expense for the twelve months ending June 30, 2024 was $-0.798B, a 18.24% decline year-over-year.
- Merck annual total non-operating income/expense for 2023 was $-1.065B, a 42.06% decline from 2022.
- Merck annual total non-operating income/expense for 2022 was $-1.838B, a 370.29% decline from 2021.
- Merck annual total non-operating income/expense for 2021 was $0.68B, a 115.87% increase from 2020.
Merck Annual Total Non-Operating Income/Expense
(Millions of US $) |
| 2023 |
$-1,065 |
| 2022 |
$-1,838 |
| 2021 |
$680 |
| 2020 |
$315 |
| 2019 |
$-755 |
| 2018 |
$-230 |
| 2017 |
$-276 |
| 2016 |
$-840 |
| 2015 |
$-2,146 |
| 2014 |
$10,600 |
| 2013 |
$-2,120 |
| 2012 |
$-1,138 |
| 2011 |
$-1,642 |
| 2010 |
$-1,702 |
| 2009 |
$11,269 |
Merck Quarterly Total Non-Operating Income/Expense
(Millions of US $) |
| 2024-06-30 |
$-122 |
| 2024-03-31 |
$-90 |
| 2023-12-31 |
$-334 |
| 2023-09-30 |
$-252 |
| 2023-06-30 |
$-323 |
| 2023-03-31 |
$-156 |
| 2022-12-31 |
$26 |
| 2022-09-30 |
$-523 |
| 2022-06-30 |
$-580 |
| 2022-03-31 |
$-761 |
| 2021-12-31 |
$158 |
| 2021-09-30 |
$343 |
| 2021-06-30 |
$21 |
| 2021-03-31 |
$158 |
| 2020-12-31 |
$-46 |
| 2020-09-30 |
$199 |
| 2020-06-30 |
$305 |
| 2020-03-31 |
$-143 |
| 2019-12-31 |
$52 |
| 2019-09-30 |
$-267 |
| 2019-06-30 |
$-199 |
| 2019-03-31 |
$-341 |
| 2018-12-31 |
$-247 |
| 2018-09-30 |
$1 |
| 2018-06-30 |
$-180 |
| 2018-03-31 |
$196 |
| 2017-12-31 |
$-157 |
| 2017-09-30 |
$54 |
| 2017-06-30 |
$-93 |
| 2017-03-31 |
$-80 |
| 2016-12-31 |
$-365 |
| 2016-09-30 |
$-183 |
| 2016-06-30 |
$-153 |
| 2016-03-31 |
$-139 |
| 2015-12-31 |
$-1,136 |
| 2015-09-30 |
$57 |
| 2015-06-30 |
$-930 |
| 2015-03-31 |
$-137 |
| 2014-12-31 |
$10,285 |
| 2014-09-30 |
$-210 |
| 2014-06-30 |
$487 |
| 2014-03-31 |
$38 |
| 2013-12-31 |
$-672 |
| 2013-09-30 |
$-940 |
| 2013-06-30 |
$-240 |
| 2013-03-31 |
$-268 |
| 2012-12-31 |
$-630 |
| 2012-09-30 |
$-152 |
| 2012-06-30 |
$-105 |
| 2012-03-31 |
$-251 |
| 2011-12-31 |
$-414 |
| 2011-09-30 |
$-24 |
| 2011-06-30 |
$-734 |
| 2011-03-31 |
$-470 |
| 2010-12-31 |
$-261 |
| 2010-09-30 |
$-922 |
| 2010-06-30 |
$-202 |
| 2010-03-31 |
$-317 |
| 2009-12-31 |
$6,697 |
| 2009-09-30 |
$3,437 |
| 2009-06-30 |
$546 |
| 2009-03-31 |
$589 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$300.492B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
